The Israel-based company said it plans to start shipping product internationally within two weeks
() announced Friday that it has kicked off production of its Derma CBD line of commercial products in Portugal.
The first product off the line will be InnoCan’s patent-pending Relief & Go CBD Spray, which was developed by chief technology officer, Nir Avram.
"The patent-pending unique formulation of Relief & Go CBD Spray contains CBD isolate as anti inflammatory, magnesium as muscle relaxant, [and] menthol and camphor as analgesics to provide temporary relief of muscle and joint pain, before and after sports activity,” Avram said in a statement. “I believe this is an effective product, which will be very successful in the market."
READ: Innocan Pharma amends unit price of $10M offering
The Israel-based company said it plans to start shipping product internationally within two weeks.
"The commencement of the production of our Derma CBD line is a significant milestone on the way to transforming our company from a research and development company to a commercial revenue generating enterprise,” CEO Iris Bincovich added.
“We expect to ship samples and products within 2 weeks to countries [such as the] UK, Germany, France [and the] US, among others. The anticipated revenues from our Derma Cosmetic Premium brands, Relieve & Go and Shir Beauty & Science, will result in revenue in the near future".
InnoCan Pharma, through its wholly-owned subsidiary, InnoCan Israel, is a pharmaceutical tech company developing products that harness the unique properties of cannabinoids combined with smart delivery formulations. InnoCan and Tel Aviv University are collaborating on developing a new exosome-based technology that targets both central nervous system disorders and the coronavirus (COVID-19).
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel
